Aims: The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis variant (ATTRv) are based on expert opinion. We aimed to (i) determine the penetrance of ATTRv cardiomyopathy (ATTRv-CM) at baseline; (ii) examine the value of serial evaluation; and (iii) establish the yield of first-line diagnostic tests (i.e. electrocardiogram, echocardiogram, and laboratory tests) as per 2021 ESC position statement. Methods and results: We included 159 relatives (median age 55.6 [43.2-65.9] years, 52% male) at risk for ATTRv-CM from 10 centres. The primary endpoint, ATTRv-CM diagnosis, was defined as the presence of (i) cardiac tracer uptake in bone scintigraphy; or (ii) transthyretin-positive cardiac biopsy. The secondary endpoint was a composite of heart failure (New York Heart Association class ≥II) and pacemaker-requiring conduction disorders. At baseline, 40/159 (25%) relatives were diagnosed with ATTRv-CM. Of those, 20 (50%) met the secondary endpoint. Indication to screen (≤10 years prior to predicted disease onset and absence of extracardiac amyloidosis) had an excellent negative predictive value (97%). Other pre-screening predictors for ATTRv-CM were infrequently identified variants and male sex. Importantly, 13% of relatives with ATTRv-CM did not show any signs of cardiac involvement on first-line diagnostic tests. The yield of serial evaluation (n = 41 relatives; follow-up 3.1 [2.2-5.2] years) at 3-year interval was 9.4%. Conclusions: Screening according to the 2021 ESC position statement performs well in daily clinical practice. Clinicians should adhere to repeating bone scintigraphy after 3 years, as progressing to ATTRv-CM without signs of ATTRv-CM on first-line diagnostic tests or symptoms is common.
Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis / Muller, Steven A; Peiró-Aventin, Belén; Biagioni, Giulia; Tini, Giacomo; Saturi, Giulia; Kronberger, Christina; Achten, Anouk; Dobner, Stephan; Te Rijdt, Wouter P; Gasperetti, Alessio; Te Riele, Anneline S J M; Varrà, Guerino G; Ponziani, Alberto; Hirsch, Alexander; Porcari, Aldostefano; van der Meer, Manon G; Zampieri, Mattia; van der Harst, Pim; Kammerlander, Andreas; Biagini, Elena; van Tintelen, J Peter; Barbato, Emanuele; Asselbergs, Folkert W; Menale, Silvia; Gräni, Christoph; Merlo, Marco; Michels, Michelle; Knackstedt, Christian; Nitsche, Christian; Longhi, Simone; Musumeci, Beatrice; Cappelli, Francesco; Garcia-Pavia, Pablo; Oerlemans, Marish I F J. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1879-0844. - STAMPA. - (2024), pp. 1-10. [10.1002/ejhf.3339]
Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis
Biagioni, Giulia;Zampieri, Mattia;Menale, Silvia;Cappelli, Francesco;
2024
Abstract
Aims: The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis variant (ATTRv) are based on expert opinion. We aimed to (i) determine the penetrance of ATTRv cardiomyopathy (ATTRv-CM) at baseline; (ii) examine the value of serial evaluation; and (iii) establish the yield of first-line diagnostic tests (i.e. electrocardiogram, echocardiogram, and laboratory tests) as per 2021 ESC position statement. Methods and results: We included 159 relatives (median age 55.6 [43.2-65.9] years, 52% male) at risk for ATTRv-CM from 10 centres. The primary endpoint, ATTRv-CM diagnosis, was defined as the presence of (i) cardiac tracer uptake in bone scintigraphy; or (ii) transthyretin-positive cardiac biopsy. The secondary endpoint was a composite of heart failure (New York Heart Association class ≥II) and pacemaker-requiring conduction disorders. At baseline, 40/159 (25%) relatives were diagnosed with ATTRv-CM. Of those, 20 (50%) met the secondary endpoint. Indication to screen (≤10 years prior to predicted disease onset and absence of extracardiac amyloidosis) had an excellent negative predictive value (97%). Other pre-screening predictors for ATTRv-CM were infrequently identified variants and male sex. Importantly, 13% of relatives with ATTRv-CM did not show any signs of cardiac involvement on first-line diagnostic tests. The yield of serial evaluation (n = 41 relatives; follow-up 3.1 [2.2-5.2] years) at 3-year interval was 9.4%. Conclusions: Screening according to the 2021 ESC position statement performs well in daily clinical practice. Clinicians should adhere to repeating bone scintigraphy after 3 years, as progressing to ATTRv-CM without signs of ATTRv-CM on first-line diagnostic tests or symptoms is common.File | Dimensione | Formato | |
---|---|---|---|
European J of Heart Fail - 2024 - Muller - Evaluation of the 2021 ESC recommendations for family screening in hereditary.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.52 MB
Formato
Adobe PDF
|
1.52 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.